Fauci: Borrowed Cash Won't Carry Zika Efficacy Trials
Cash borrowed from various US government programs, including the Ebola response, is enough to get at least two Phase I Zika vaccine trials underway, but those funds won't carry the efficacy studies – the preparations of which must get off the ground next month. So Congress needs to allocate new dollars within the next few weeks or the Phase II trials will be in jeopardy, Anthony Fauci, the nation's top infectious disease official, told Scrip.
You may also be interested in...
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.
GlaxoSmithKline PLC has offered up its new Maryland vaccine research and development center, and its scientists, under the company's proposal to establish a global collaboration for the pursuit of products that are commercially risky, but necessary to address emerging infectious diseases, before a public health crisis strikes.
A $1.1bn Zika funding measure failed in a Senate procedural vote on June 28, leaving US government agencies to continue their work on dollars borrowed from other programs, while Republicans and Democrats argued over who's to blame.